ArticleClinical and molecular hepatology2026

Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma.

Hideki Iwamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.